shire map
Select a
Location

Shire Global

Newsroom

Director/PDMR Shareholding

February 29, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that on February 26, 2016, Stock Appreciation Rights (“SARs”) and Restricted Stock Units (“RSUs”) were granted to Persons Discharging Managerial Responsibilities (“PDMRs”) under the Shire Long Term Incentive Plan 2015 (“LTIP”). SARs and RSUs will normally vest after three years, subject to any performance conditions being satisfied, with no consideration payable for these awards. The awards were granted over notional American Depositary Shares (“ADSs”) in the Company as follows:

PDMR

Type of Award(1),(2)

Number of ADSs(3)

Exercise Price

Flemming Ornskov

SAR

43,329

$161.42

 

RSU

32,497

Nil

 

 

 

 

Jeff Poulton

SAR

13,681

$161.42

 

RSU

10,261

Nil

 

 

 

 

Mark Enyedy

SAR

11,616

$161.42

 

RSU

10,455

Nil

 

 

 

 

Ginger Gregory

SAR

8,113

$161.42

 

RSU

7,302

Nil

 

 

 

 

Bill Mordan

SAR

9,680

$161.42

 

RSU

8,712

Nil

 

 

 

 

Phil Vickers

SAR

11,063

$161.42

 

RSU

9,957

Nil

 

 

 

 

(1) SARs and RSUs granted under the LTIP correspond to SARs and Performance Share Awards (“PSAs”) granted under the legacy Shire Portfolio Share Plan, as referenced in the Directors’ Remuneration Report in the 2014 Annual Report and Accounts.

(2) SARs and RSUs granted to Dr. Ornskov and Mr. Poulton, and RSUs granted to the remainder of the PDMRs, are subject to performance conditions. Upon normal vesting, any ADSs to be delivered to Dr. Ornskov and Mr. Poulton will be subject to a retention period of two years in accordance with the rules of the LTIP.

(3) One ADS is equal to three Ordinary Shares of 5 pence each in the Company.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations

 

 

Sarah Elton-Farr

seltonfarr@shire.com

+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE